Mark Schoenebaum News
-
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
-
Eli Lilly & Co. halted development of an experimental cancer drug after the medicine failed to lengthen survival for certain lymphoma patients in a study.
-
Gilead Sciences Inc. is moving its experimental drug combination against hepatitis C into a late- stage trial after it cured 95 percent of patients who used the medicine for eight weeks.
-
Gilead Sciences Inc., the world’s biggest maker of AIDS medicines, reported first-quarter profit that missed analysts’ estimates on declining sales of its HIV drugs.
-
Merck & Co., facing generic competition to what was once its best-selling drug, cut its full-year guidance in anticipation of lower sales and said it would start buying back as much as $15 billion in shares.
-
Actavis Inc., the generic drugmaker whose merger negotiations with Valeant Pharmaceuticals International Inc. stalled over price, may deserve the industry’s second-best valuation ever in a deal.
-
Pfizer Inc., the world’s biggest drugmaker, reduced its 2013 profit forecast after first-quarter sales missed analyst estimates. The shares had their worst one- day loss since August 2011.
-
The introduction of Biogen Idec Inc.’s multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis AG and Sanofi, suggesting the treatment may beat estimates for the year.
-
Pfizer Inc.’s rheumatoid arthritis pill failed to win the backing of European drug regulators, who said the drug already approved in the U.S. isn’t effective enough against the condition.
-
Eli Lilly & Co. said first-quarter profit exceeded analysts’ estimates as the company cut jobs and had a lower tax rate from the reinstatement of a research and development credit.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page